Conspiracy among Pharma front groups alleged in PharmacyChecker.com lawsuit

16 August 2019

Brand name medicines often cost 80%-90% less from licensed pharmacies in Canada and other countries than from pharmacies in the USA.

However, according to a lawsuit filed this week by PharmacyChecker.com in the Southern District Court of New York, an alleged conspiracy involving front groups for Big Pharma is keeping these lower priced drugs out of reach of millions of Americans.

PharmacyChecker.com claims to be the only independent company monitoring and verifying the credentials of international online pharmacies and comparing prices of the prescription drugs available from these licensed pharmacies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK